(19)
(11) EP 1 909 901 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
02.02.2011 Bulletin 2011/05

(45) Mention of the grant of the patent:
01.12.2010 Bulletin 2010/48

(21) Application number: 06787437.0

(22) Date of filing: 13.07.2006
(51) International Patent Classification (IPC): 
A61N 5/00(2006.01)
(86) International application number:
PCT/US2006/027526
(87) International publication number:
WO 2007/015774 (08.02.2007 Gazette 2007/06)

(54)

COMPOSITIONS FOR TREATING LUMINAL INFLAMMATORY DISEASE

ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON LUMINALEN ENTZÜNDLICHEN ERKRANKUNGEN

COMPOSITIONS DESTINEES AU TRAITEMENT DE MALADIES LUMINALES INFLAMMATOIRES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: 20.07.2005 US 701371 P

(43) Date of publication of application:
16.04.2008 Bulletin 2008/16

(73) Proprietor: Clear Vascular, Inc.
The Woodlands, TX 77380 (US)

(72) Inventors:
  • GONZALES, Gilbert, R.
    New York, New York 10021 (US)
  • CHRONOS, Nicolas
    Atlanta, Georgia 30327 (US)

(74) Representative: Evenson, Jane Harriet et al
Mathys & Squire LLP 120 Holborn
London EC1N 2SQ
London EC1N 2SQ (GB)


(56) References cited: : 
US-A- 5 216 130
US-A- 5 711 931
US-A1- 2003 152 513
 US-A- 5 216 130
US-A1- 2003 082 105
US-B1- 6 500 108
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).